AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders

Edward L. Barnes, Manasi Agrawal, Gaurav Syal, Ashwin N. Ananthakrishnan, Benjamin L. Cohen, John P. Haydek, Elie S. Al Kazzi, Samuel Eisenstein, Jana G. Hashash, Shahnaz S. Sultan, Laura E. Raffals, Siddharth Singh, AGA Clinical Guidelines Committee

Research output: Contribution to journalJournal articleResearchpeer-review

3 Citations (Scopus)


BACKGROUND & AIMS: Pouchitis is the most common complication after restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. This American Gastroenterological Association (AGA) guideline is intended to support practitioners in the management of pouchitis and inflammatory pouch disorders.

METHODS: A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation framework to prioritize clinical questions, identify patient-centered outcomes, conduct an evidence synthesis, and develop recommendations for the prevention and treatment of pouchitis, Crohn's-like disease of the pouch, and cuffitis.

RESULTS: The AGA guideline panel made 9 conditional recommendations. In patients with ulcerative colitis who have undergone ileal pouch-anal anastomosis and experience intermittent symptoms of pouchitis, the AGA suggests using antibiotics for the treatment of pouchitis. In patients who experience recurrent episodes of pouchitis that respond to antibiotics, the AGA suggests using probiotics for the prevention of recurrent pouchitis. In patients who experience recurrent pouchitis that responds to antibiotics but relapses shortly after stopping antibiotics (also known as "chronic antibiotic-dependent pouchitis"), the AGA suggests using chronic antibiotic therapy to prevent recurrent pouchitis; however, in patients who are intolerant to antibiotics or who are concerned about the risks of long-term antibiotic therapy, the AGA suggests using advanced immunosuppressive therapies (eg, biologics and/or oral small molecule drugs) approved for treatment of inflammatory bowel disease. In patients who experience recurrent pouchitis with inadequate response to antibiotics (also known as "chronic antibiotic-refractory pouchitis"), the AGA suggests using advanced immunosuppressive therapies; corticosteroids can also be considered in these patients. In patients who develop symptoms due to Crohn's-like disease of the pouch, the AGA suggests using corticosteroids and advanced immunosuppressive therapies. In patients who experience symptoms due to cuffitis, the AGA suggests using therapies that have been approved for the treatment of ulcerative colitis, starting with topical mesalamine or topical corticosteroids. The panel also proposed key implementation considerations for optimal management of pouchitis and Crohn's-like disease of the pouch and identified several knowledge gaps and areas for future research.

CONCLUSIONS: This guideline provides a comprehensive, patient-centered approach to the management of patients with pouchitis and other inflammatory conditions of the pouch.

Original languageEnglish
Issue number1
Pages (from-to)59-85
Number of pages27
Publication statusPublished - Jan 2024

Bibliographical note

Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.


  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents/therapeutic use
  • Colitis, Ulcerative/diagnosis
  • Crohn Disease/diagnosis
  • Humans
  • Pouchitis/diagnosis
  • Proctocolectomy, Restorative/adverse effects
  • Ileal Pouch–Anal Anastomosis
  • Pouchitis
  • J-Pouch
  • Inflammatory Bowel Disease
  • Evidence Synthesis


Dive into the research topics of 'AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders'. Together they form a unique fingerprint.

Cite this